中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 药物制剂研究中心
Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis

文献类型：期刊论文

作者Kang, Xuejia1,4; Zheng, Zenin1,4; Liu, Zehua1,4; Wang, Huiyuan1; Zhao, Yuge1,3; Zhang, Wenyuan1; Shi, Mingjie1; He, Yang1; Cao, Yang2; Xu, Qin4
刊名MOLECULAR PHARMACEUTICS
出版日期2018-04
卷号15期号:4页码:1618-1626
关键词cell-penetrating peptide doxorubicin andrographolide liposome angiogenesis breast cancer
ISSN号1543-8384
DOI10.1021/acs.molpharmaceut.7b01164
文献子类Article
英文摘要Effective treatment of metastatic (stage N) breast cancers remains a formidable challenge. To address this issue, a cell-penetrating peptide assisted liposomal system was developed for codelivery of doxorubicin and andrographolide. This nanomedicine-based combination therapy showed the ability to inhibit the in vitro migration and invasion of 4T1 cells through the wound healing and transwell invasion assays. Furthermore, this delivery system exhibited the enhanced accumulation in the tumor tissues and deep intratumoral penetration. The synergistic effect of doxorubicin and andrographolide led to an evident inhibition of tumor growth in an orthotopic breast tumor mouse model and efficient prevention of lung metastasis. The therapeutic mechanism was associated with the anti-angiogenesis effect. In conclusion, this nanomedicine-based combination therapy provides a potential method for overcoming metastatic breast cancers.
WOS关键词CELL-PENETRATING PEPTIDES ; MULTIDRUG-RESISTANT CANCER ; DELIVERY ; ANGIOGENESIS ; THERAPY
资助项目973 Program, China[2014CB931900] ; NFSC[81402883] ; NFSC[81422048] ; NFSC[81673382] ; NFSC[81521005] ; Strategic Priority Research Program of CAS[XDA12050307] ; Scientific Research and Equipment Development Project[YZ201437] ; SANOFI-SIBS Scholarship Program[00000000] ; Youth Innovation Promotion Association of CAS[00000000] ; Fudan-SIMM Joint Research Fund[FU-SIMM20174009]
WOS研究方向Research & Experimental Medicine ; Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000429283300024
出版者AMER CHEMICAL SOC
源URL[http://119.78.100.183/handle/2S10ELR8/279829]  
专题药物制剂研究中心
通讯作者Xu, Qin; Huang, Yongzhuo
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China;
2.Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510405, Guangdong, Peoples R China
3.Nanchang Univ, Coll Pharm, 461 Bayi Rd, Nanchang 330006, Jiangxi, Peoples R China;
4.Guangzhou Univ Chinese Med, Inst Trop Med, Guangzhou 510405, Guangdong, Peoples R China;
推荐引用方式
GB/T 7714		 Kang, Xuejia,Zheng, Zenin,Liu, Zehua,et al. Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis[J]. MOLECULAR PHARMACEUTICS,2018,15(4):1618-1626.
APA Kang, Xuejia.,Zheng, Zenin.,Liu, Zehua.,Wang, Huiyuan.,Zhao, Yuge.,...&Huang, Yongzhuo.(2018).Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis.MOLECULAR PHARMACEUTICS,15(4),1618-1626.
MLA Kang, Xuejia,et al."Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis".MOLECULAR PHARMACEUTICS 15.4(2018):1618-1626.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。